"V体育官网" Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation
- PMID: 12679650
- DOI: 10.1097/00043426-200304000-00013
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation (VSports最新版本)
Abstract (VSports最新版本)
Childhood B-cell neoplasms account for approximately 2% of childhood acute lymphoblastic leukemia (ALL). The short but intensive chemotherapy yields a currently 75% to 85% event-free survival. The prognosis for children with relapsed disease is considered to be dismal. We report a 12-year old boy diagnosed with B-cell ALL with central nervous system (CNS) involvement. He relapsed in the bone marrow immediately after primary chemotherapy. Rituximab as a single agent achieved a complete morphologic remission. After 4 treatments with rituximab an isolated CNS relapse occurred. CNS remission was reinduced with chemotherapy and the patient received an autologous transplant with rituximab for in vivo purging. He is currently in complete clinical and molecular remission for more than 1 year VSports手机版. .
Publication types
- "VSports在线直播" Actions
MeSH terms
- Actions (V体育平台登录)
- VSports在线直播 - Actions
- V体育2025版 - Actions
- Actions (VSports)
- "VSports最新版本" Actions
- VSports手机版 - Actions
- VSports最新版本 - Actions
- Actions (V体育ios版)
- Actions (V体育2025版)
- Actions (V体育2025版)
- Actions (V体育安卓版)
- Actions (VSports最新版本)
- Actions (VSports手机版)
Substances
- VSports手机版 - Actions
- "V体育2025版" Actions
- VSports在线直播 - Actions
- Actions (VSports在线直播)
LinkOut - more resources
Full Text Sources
